EARLY DETECTION SAVES LIVES — AND AWARENESS DRIVES ACTION

During Breast Cancer Awareness Month (October), Dr. Angela Pang, Senior Medical Oncologist at OncoCare Cancer Center, joined the 365 Cancer Prevention Society’s live broadcast to raise awareness about cancer prevention and early detection.

 

🔎 Key highlights:
In most developed countries, including Singapore, breast cancer is the most common cancer among women, surpassing colorectal and lung cancers. Early-stage detection leads to simpler, more effective treatments, while late detection often requires more complex and prolonged therapy.

+ Localized breast cancer: nearly 99% 5-year survival rate

+ Advanced breast cancer: only 29%

+ Early screening programs have reduced breast cancer mortality by up to 40%.

 

Next-generation screening: MCED (Multi-Cancer Early Detection)
Dr. Pang introduced blood-based MCED tests that analyze circulating tumor DNA (ctDNA) to detect early signals of 10 major cancer types (75 subtypes) — all from a single blood draw.

 

💗 October’s message – The Power of Awareness:
“Be proactive, not fearful. Awareness empowers prevention.”
Encouraging public participation and regular screening can help detect cancers earlier and improve survival outcomes.

 

👉 Let’s support each other — encourage your loved ones to take charge of their health and sign up for screening today.

 

👉  Watch the full live session here: https://www.facebook.com/watch/live/?ref=watch_permalink&v=2629044210778092

#MCED #EarlyDetection #CancerPrevention #BreastCancerAwareness #GeneSolutions

 

LATEST News

ESMO 2026 Gene Solutions Global Industry Satellite Symposium AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation

From Asia to the Global Oncology Stage: Gene Solutions Contributes Multi-Omic Innovation at ESMO Congress 2026

MADRID, Nov. 18, 2026 — Gene Solutions hosted its first Global Industry Satellite Symposium, sharing multi-omic liquid biopsy technologies and the clinical and real-world data generated in Asia with the international oncology community. The achievement reflects the company’s evolution from an Asia-based genetic testing pioneer to a globally engaged innovator of cell-free DNA technologies span ning cancer screening, precision oncology, and functional applications.     ESMO Congress, one of the world’s leading oncology meetings, brought together more than 40,000 participants from the global cancer community in Madrid in 2026 for the largest congress in ESMO’s history. The meeting provided a

Read More
Panel Discussion​ | Bridging Regional Evidence to Global Precision Oncology: Challenges and Opportunities in Multi-Omic Liquid Biopsy Implementation Across the Cancer Care Continuum ESMO 2026 Gene Solutions

Inside Gene Solutions’ ESMO 2026 Symposium and Scientific Program: Six Perspectives Across the Cancer Care Continuum

At ESMO Congress 2026 in Madrid, Gene Solutions hosted its first Industry Satellite Symposium at the main ESMO Congress, bringing clinical validation, real-world experience, and multi-omic innovation generated in Asia into the global oncology conversation.  The full-house symposium, “AI-Enabled Multi-omic Liquid Biopsy Across the Cancer Care Continuum: From Technological Innovation to Scalable Clinical Implementation,” brought together six international faculty members to share scientific and clinical perspectives on the future of cancer detection and precision oncology.  Co-chaired by Prof. Umberto Malapelle of the University of Naples Federico II and Prof. Herbert Ho Fung Loong of The Chinese University of Hong Kong,

Read More
New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More